Search Result

Results for "

CDC-25

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (2) Akt (2) Androgen Receptor (2) Apoptosis (15) Autophagy (2) Bacterial (1) Bcl-2 Family (1) Biochemical Assay Reagents (1) c-Myc (1) Caspase (5) CDK (9) Checkpoint Kinase (Chk) (2) DNA/RNA Synthesis (4) Epigenetic Reader Domain (1) Ferroptosis (2) FGFR (1) Fungal (2) GSK-3 (1) Histone Methyltransferase (2) IRE1 (2) JNK (3) MAPKAPK2 (MK2) (1) MDM-2/p53 (2) Microtubule/Tubulin (1) mTOR (2) Necroptosis (1) p38 MAPK (1) Parasite (1) Phosphatase (27) PI3K (1) PKC (1) Polo-like Kinase (PLK) (2) PROTACs (2) PSMA (2) Ras (1) Reactive Oxygen Species (ROS) (4) Reference Standards (3) SHP1 (1) Small Interfering RNA (siRNA) (10) STAT (1) Wee1 (1) YAP (2)
By Research Areas:	Cancer (44) Infection (3) Inflammation/Immunology (5) Metabolic Disease (1)
Oligonucleotides:	Rat Pre-designed siRNA Sets (3) Mouse Pre-designed siRNA Sets (3) Human Pre-designed siRNA Sets (4) siRNAs (10)

Inhibitors & Agonists

Peptides

Natural
Products

Antibodies

Oligonucleotides

Targets Recommended: Cdc42-binding kinase Ack1 p97

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-107407

SB-218078 5 Publications Verification	Checkpoint Kinase (Chk) CDK PKC Apoptosis	Cancer
SB-218078 is a potent, selective, ATP-competitive and cell-permeable checkpoint kinase 1 (Chk1) inhibitor that inhibits Chk1 phosphorylation of cdc25C with an IC₅₀ of 15 nM. SB-218078 is less potently inhibits *Cdc2* (IC₅₀ of 250 nM) and PKC (IC₅₀ of 1000 nM). SB-218078 causes apoptosis by DNA damage and cell cycle arrest .

HY-108543

NSC 95397 Maximum Cited Publications 9 Publications Verification	Phosphatase Apoptosis	Cancer
NSC 95397 is a potent, selective *Cdc25* dual specificity phosphatase inhibitor (K_i=32 nM (Cdc25A), 96 nM (Cdc25B), 40 nM (Cdc25C); IC₅₀=22.3 nM (human Cdc25A), 56.9 nM (human Cdc25C), 125 nM (Cdc25B)) . NSC 95397 inhibits mitogen-activated protein kinase phosphatase-1 (MKP-1) and suppresses proliferation and induces apoptosis in colon cancer cells through MKP-1 and ERK1/2 pathway .

HY-100034

NSC 663284 5+ Cited Publications DA-3003-1	Phosphatase Histone Methyltransferase	Cancer
NSC 663284 (DA-3003-1) is a potent, cell-permeable, and irreversible Cdc25 dual specificity phosphatase inhibitor, has an IC₅₀ for Cdc25B2 of 0.21 μM. NSC 663284 exhibits mixed competitive kinetics against Cdc25A, Cdc25B(2), and Cdc25C with Ki values of 29, 95, and 89 nM, respectively . NSC 663284 inhibits NSD2 (IC₅₀ of 170 nM) through a direct interaction with the catalytic SET domain (K_d of 370 nM) .

HY-112356

Scytonemin	Apoptosis Reactive Oxygen Species (ROS) Polo-like Kinase (PLK)	Inflammation/Immunology Cancer
Scytonemin is a hydrophobic alkaloid pigment that can be isolated from the outer sheath of cyanobacteria. Scytonemin has protective function against short-wave solar ultraviolet (UV) radiation, which can reduce the generation of reactive oxygen species (ROS) and the formation of DNA damage. Scytonemin also has anti-inflammatory and anti-proliferative activities, produces concentration-dependent inhibition (IC₅₀=2.0 μM) of polo-like kinase 1 (PLK1)-mediated cdc25C phosphorylation, and plays an important role in regulating the G2/M transition in the cell cycle. It can be used in the research of cancer, acute inflammation and sunscreen cosmetics .

HY-151986

FOXM1-IN-1	DNA/RNA Synthesis	Cancer
FOXM1-IN-1 is a potent FOXM1 inhibitor with an IC₅₀ value of 2.65 µM. FOXM1-IN-1 shows antiproliferative activity. FOXM1-IN-1 decreases the the expression of FOXM1, PLK1, CDC25B protein .

HY-N5112A

β,β-Dimethylacrylalkannin 3 Publications Verification Arnebin 1	FGFR Necroptosis Apoptosis CDK JNK	Inflammation/Immunology
β,β-Dimethylacrylalkannin (Arnebin 1) is an orally active FGFR1 inhibitor (IC₅₀=2.5 μM) and the main active component of Lithospermum erythrorhizon. β,β-Dimethylacrylalkannin blocks downstream signaling by binding to the ATP pocket of FGFR1, and regulates the *CDK1/Cdc25C* pathway and ROS-JNK axis, thereby inducing G2/M phase arrest, necrosis and apoptosis in cancer cells, and inhibiting tumor proliferation. β,β-Dimethylacrylalkannin also acts as a colistin adjuvant to disrupt the cell membrane of Gram-negative bacteria. β,β-Dimethylacrylalkannin exhibits significant tumor-inhibitory effects with no obvious toxicity in PDX models, but chronic exposure to high doses may alter the relative lung/liver weights of rats, while acute exposure to high doses causes responses such as reduced motor activity. β,β-Dimethylacrylalkannin finds wide application in studies related to hepatocellular carcinoma, colorectal cancer, colistin-resistant bacterial infections, hepatitis and psoriasis .

HY-N7045

Isosilybin B 2 Publications Verification	Androgen Receptor Apoptosis CDK Caspase PSMA	Cancer
Isosilybin B is a flavonolignan. Isosilybin B can be isolated from Silybum marianum. Isosilybin B can regulate cell cycle-related proteins (e.g., reduce cyclins (D3, D1, A, E), Cdk4, Cdk2, *Cdc25A), and activate Caspases* (Caspase-9 and Caspase-3). Isosilybin B can promote Apoptosis, reduce androgen receptor (AR) and PSA. Isosilybin B has anticancer activity against prostate cancer .

HY-112776

BN82002	Phosphatase	Cancer
BN82002 is a potent, selective and irreversible inhibitor of CDC25 phosphatase family. BN82002 inhibits CDC25A, CDC25B2, CDC25B3, CDC25C CDC25A, and 25C-cat with IC₅₀ values of 2.4, 3.9, 6.3, 5.4, and 4.6 µM, respectively. BN82002 displays ~20-fold greater selectivity over CD45 tyrosine phosphatase .

HY-135457

JMS-053 3 Publications Verification	Phosphatase STAT Ras	Cancer
JMS-053 is an efficient and reversible PTP4A3 inhibitor, with an IC₅₀ value of 18 nM. JMS-053 demonstrates broad PTP4A inhibitory activity with IC₅₀s of 50 nM and 53 nM for PTP4A1 and PTP4A2, respectively. JMS-053 exhibits IC₅₀ values of 92.6 nM and 207.6 nM for *CDC25B* and DUSP3, respectively. JMS-053 can effectively inhibit the activity of PTP4A3, inhibit tumor cell proliferation and migration through multiple mechanisms such as interfering with RhoA and STAT3/p38 signaling pathway. JMS-053 can be used for the study of cancers such as ovarian cancer, breast cancer and colon cancer .

HY-132578

M5N36	Phosphatase	Cancer
M5N36 is a potent and selective *Cdc25C* inhibitor with IC₅₀ values of 0.15, 0.19, 0.06 µM for Cdc25A, Cdc25B, Cdc25C, respectively. M5N36 shows anti-proliferative activity and increases the expression of p-CDK1 and p-CDK2 .

HY-126246

CDC25B-IN-1 1 Publications Verification	Phosphatase	Cancer
CDC25B-IN-1 (compound 4a) is a potent inhibitor of *cell division cycle 25B (CDC25B) phosphatase, with a K_i* of 8.5 μM. CDC25B-IN-1 potently inhibits cell proliferation and colony formation, causes an increase of the G2/M phase .

HY-112776A

BN82002 hydrochloride 1 Publications Verification	Phosphatase	Cancer
BN82002 hydrochloride is a potent, selective and irreversible inhibitor of CDC25 phosphatase family. BN82002 hydrochloride inhibits CDC25A, CDC25B2, CDC25B3, CDC25C CDC25A, and 25C-cat with IC₅₀ values of 2.4, 3.9, 6.3, 5.4, and 4.6 µM, respectively. BN82002 hydrochloride displays ~20-fold greater selectivity over CD45 tyrosine phosphatase .

HY-121065

BN-82685 IRC-083065	Phosphatase	Cancer
BN-82685 is a a quinone-based *CDC25* inhibitor with IC₅₀ of 201 nM, 117 nM, 109 nM, 160 nM, 249 nM, for CDC25C, CDC25C-cat, CDC25A, CDC25B2, CDC25B3, respectively. BN-82685 plays an important role in cancer research .

HY-N3000

6-Methoxydihydrosanguinarine	JNK IRE1 Akt mTOR YAP Reactive Oxygen Species (ROS) Autophagy Apoptosis Ferroptosis Fungal	Infection Inflammation/Immunology Cancer
6-Methoxydihydrosanguinarine is an alkaloid with activity across multiple cancer cell types. 6-Methoxydihydrosanguinarine activates IRE1/JNK signaling, blocks Akt/mTOR and PI3K/AKT/mTOR pathways, reduces expression of Cdc25C, CyclinB1, Cdc2, YAP/TAZ, Survivin, GPX4, and EGFR, upregulates IRE1 and DR5, and activates JNK and caspases. 6-Methoxydihydrosanguinarine induces apoptosis, G2/M phase arrest, DNA damage, ROS generation, lipid peroxidation, ferroptosis, autophagy, and suppresses cancer cell growth. 6-Methoxydihydrosanguinarine disruptes the biofilm formation of Candida albicans (C. albicans). 6-Methoxydihydrosanguinarine can be used for the research of non-small cell lung cancer, hepatocellular carcinoma, melanoma, colon carcinoma, ovarian cancer and breast cancer .

HY-118798

DA 3003-2 NSC663285	Phosphatase	Cancer
DA 3003-2 is a potent and selectively *Cdc25* inhibitor. DA 3003-2 shows antiproliferative activity. DA 3003-2 induces cell cycle arrest at the G2/M phase and increases the expression of P-tyr ¹⁵ Cdc2. DA 3003-2 has the potential for the research of prostate cancer .

HY-103381

NSC693868	CDK GSK-3	Cancer
NSC693868 is a selective inhibitor of CDK1 and CDK5 with IC₅₀s of 600 nM and 400 nM, respectively. NSC693868 less potently inhibits GSK3β with an IC₅₀ of 1 µM) and does not block CDC25 activity. NSC693868 is used to help define the roles of CDK1 and CDK5 in various signaling pathways .

HY-W024644

Hydroxyethylthio Vitamine K3	Phosphatase	Cancer
Hydroxyethylthio Vitamin K3 is a Cdc25 phosphatase inhibitor, with IC₅₀ values of 4.56 μM and 23.63 μM for Cdc25A and Cdc25B, respectively. Hydroxyethylthio Vitamin K3 can be used in tumor research .

HY-128769

M2N12	CDK	Cancer
M2N12 is a potent and highly selective cell division cycle 25C protein phosphatase (Cdc25C) inhibitor with an IC₅₀ value of 0.09  μM. M2N12 also has promising activity against Cdc25A and Cdc25B with IC₅₀ values of  0.53  μM and 1.39 μM, respectively. M2N12 has anti-tumor activity and can be used for cancer research .

HY-137175A

CDC25B-IN-2	Phosphatase	Cancer
CDC25B-IN-2 is a potent *cdc25B* inhibitor .

HY-172807

p38α-IN-9	p38 MAPK MAPKAPK2 (MK2) CDK Wee1	Cancer
p38α-IN-9 (Compound 2015) is a p38α inhibitor and blocks p38α’s enzymatic activity with an IC₅₀ lower than 20 nM. p38α-IN-9 inhibits MK2 ^T334 phosphorylation. p38α-IN-9 activates Cdc25b and Cdc25c and simultaneously inactivates Wee1, leading to mitotic catastrophe, aneuploidy or polyploidy and DNA damage. p38α-IN-9 Inhibits colorectal cancer (CRC) metastasis .

HY-W102931

6,7-Dichloroquinoline-5,8-dione	Phosphatase	Cancer
6,7-Dichloroquinoline-5,8-dione (compound DA3002) is a potent *CDC25B2* inhibitor with an IC₅₀ value of 4.6 µM. 6,7-Dichloroquinoline-5,8-dione has the potential for the research of cancer .

HY-178944

CDC25-IN-1	Phosphatase Apoptosis Caspase	Cancer
CDC25-IN-1 (Compound D11b) is a potent inhibitor of cell division cycle 25 (CDC25) phosphatase. CDC25-IN-1 exerts strong inhibitory effects on leukemia and colorectal cancer cells. CDC25-IN-1 blocks CDC25 mediated CDK1 Tyr15 dephosphorylation, delays G2/M progression, and induces caspase-dependent apoptosis with DNA damage. CDC25-IN-1 can be used for researches of leukemia and colorectal cancer .

HY-RS02291

CDC25A Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CDC25A Human Pre-designed siRNA Set A contains three designed siRNAs for CDC25A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CDC25A Human Pre-designed siRNA Set A CDC25A Human Pre-designed siRNA Set A

HY-137990

Questin	Bacterial Parasite Phosphatase	Infection Cancer
Questin is an anthraquinone compound and antibacterial agent. Questin can be isolated from marine-derived fungi and plants. Questin inhibits *Cdc25B* phosphatase. Questin exhibits antibacterial activity against V. harveyi, V. anguillarum, V. cholerae, and V. parahemolyticus with MIC values of 31.25 µg/mL, 62.5 µg/mL, 62.5 µg/mL, and 125 µg/mL. Questin displays antiprotozoal activity against the animal protozoan pathogen Tritrichomonas foetus, with a MIC of 12.5 µg/mL. Questin has anticancer activity against lung and colon cancer .

HY-118529

JUN-1111	Phosphatase	Cancer
JUN-1111 is an irreversible and selective Cdc25 phosphatase inhibitor with IC₅₀ values of 0.38, 1.8, 0.66, 28, 37 µM for Cdc25A, Cdc25B, Cdc25C, VHR, PTP1B, respectively. JUN-1111 induces cell cycle arrest at G1 and G2/M phases. JUN-1111 decreases the expression of phosphoCdk1 .

HY-N12177

Cryptosporioptide A	Phosphatase SHP1	Metabolic Disease
Cryptosporioptide A (Compound 3) is a pigment protein tyrosine phosphatase inhibitor derived from the insect-parasitic fungus Cordyceps gracilioides. Cryptosporioptide A inhibits PTP1B, SHP2, CDC25B, LAR and SHP1 enzymes with IC₅₀ of 7.3, 5.7, 7.6, >50, 4.9 μg/mL, respectively .

HY-181011

*PROTAC Cdc25* degrader-1**	PROTACs Phosphatase Apoptosis Reactive Oxygen Species (ROS)	Cancer
PROTAC Cdc25 degrader-1 (Compound D3) is an efficient Cdc25 PROTAC degrader. Its DC₅₀ values for *Cdc25A, Cdc25B, and Cdc25C* are 0.97, 2.02, and 4.67 μM respectively. PROTAC Cdc25 degrader-1 induces cell cycle arrest and apoptosis in cancer cells and inhibits cell migration ability. PROTAC Cdc25 degrader-1 significantly increases the ROS level. PROTAC Cdc25 degrader-1 can be used for the study of colorectal adenocarcinoma .

HY-RS18853

Cdc25c Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Cdc25c Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cdc25c gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cdc25c Mouse Pre-designed siRNA Set A Cdc25c Mouse Pre-designed siRNA Set A

HY-RS02293

CDC25C Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CDC25C Human Pre-designed siRNA Set A contains three designed siRNAs for CDC25C gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CDC25C Human Pre-designed siRNA Set A CDC25C Human Pre-designed siRNA Set A

HY-28086

CDC25-IN-2	Phosphatase	Cancer
CDC25-IN-2 (Compound 1d) is a selective phosphatase Cdc25 inhibitor with IC₅₀ values of 44.4, 55.2 and 53.9 μM for human Cdc25A, Cdc25B, Cdc25C. CDC25-IN-2 can block the cell cycle progression by inhibiting the activity of Cdc25 phosphatase. CDC25-IN-2 can be used for the research of cancer .

HY-123417

IRC-083864	Phosphatase	Cancer
IRC-083864 is an inhibitor of CDC25 phosphatase. IRC-083864 inhibits the activity of recombinant human full-length CDC25 phosphatase with an IC₅₀ value of 23 nM. IRC-083864 inhibits cell viability with an IC₅₀ value of 47 nM on the HL60 cell line .

HY-P4979

Cdc25A (80-93) (human)	Biochemical Assay Reagents	Cancer
Cdc25A (80-93) (human) is a polypeptide that controls the cell proliferation and tumorigenesis by a change in expression of proteins involved in cyclin D1 regulation and G1/S transition. Cdc25A (80-93) (human) can be used in cancer research .

HY-178297

VHR-IN-7	Phosphatase	Cancer
VHR-IN-7 is a selective vaccinia H1-related (VHR) phosphatase inhibitor with an IC₅₀ of 71 nM. VHR-IN-7 shows very weaker inhibitory activity against MKP-1 (IC₅₀ = 0.47 μM), CD45 (IC₅₀ = 0.3 μM), Cdc25A (IC₅₀ = 3.4 μM), PTP1B (IC₅₀ = 0.59 μM), and HePTP (IC₅₀ = 1.2 μM). VHR-IN-7 inhibits the proliferation of HeLa cells. VHR-IN-7 can be used for the research of cervical cancer .

HY-178296

VHR-IN-6	Phosphatase	Cancer
VHR-IN-6 is a selective vaccinia H1-related (VHR) phosphatase inhibitor with an IC₅₀ of 74 nM. VHR-IN-6 shows very weaker inhibitory activity against MKP-1 (IC₅₀ = 0.52 μM), CD45 (IC₅₀ = 0.50 μM), Cdc25A (IC₅₀ = 2.8 μM), PTP1B (IC₅₀ = 0.42 μM), and HePTP (IC₅₀ = 0.87 μM). VHR-IN-6 inhibits the proliferation of HeLa cells. VHR-IN-6 can be used for the research of cervical cancer .

HY-178301

VHR-IN-9	Phosphatase	Cancer
VHR-IN-9 is a selective vaccinia H1-related (VHR) phosphatase inhibitor with an IC₅₀ of 270 nM. VHR-IN-9 shows very weaker inhibitory activity against MKP-1 (IC₅₀ = 2.8 μM), CD45 (IC₅₀ = 1.8 μM), Cdc25A (IC₅₀ = > 10 μM), PTP1B (IC₅₀ = 2.2 μM), and HePTP (IC₅₀ = 2.4 μM). VHR-IN-9 inhibits the proliferation of HeLa cells. VHR-IN-9 can be used for the research of cervical cancer .

HY-RS02292

CDC25B Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CDC25B Human Pre-designed siRNA Set A contains three designed siRNAs for CDC25B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CDC25B Human Pre-designed siRNA Set A CDC25B Human Pre-designed siRNA Set A

HY-155816

PROTAC NSD3 degrader-1	PROTACs	Cancer
PROTAC NSD3 degrader-1 (compound 56) is a PROTAC targeting to Nuclear receptor binding SET domain protein NSD3. PROTAC NSD3 degrader-1 specifically induces NSD3 degradation with DC50 values of 1.43 and 0.94 μM in lung cancer cells NCI-H1703 and A549, respectively. PROTAC NSD3 degrader-1 suppresses the methylation of H3K36, induces apoptosis, and causes cell-cycle arrest. PROTAC NSD3 degrader-1 also downregulates the expression of NSD3-associated genes such as CDC25A, ALDH1A1, and IGFBP.

HY-175033

BRD4-IN-11	Epigenetic Reader Domain Phosphatase c-Myc Apoptosis	Inflammation/Immunology
BRD4-IN-11 is an orally active and selective BRD4 inhibitor (IC₅₀ = 26.35 nM (BD1), IC₅₀ = 72.81 nM (BD2)). BRD4-IN-11 is approximately 3- to 18-fold more potent against BRD4 than againstBRD2, BRD3, and BRDT. BRD4-IN-11 enhances H2S release and inhibits the upregulation of fibrotic markers (α-SMA and fibronectin), c-Myc, and CDC25B. BRD4-IN-11 reduces apoptosis in LO2 hepatocytes. BRD4-IN-11 significantly improves liver and lung function in a hepatopulmonary fibrosis model and can be used to study hepatopulmonary fibrosis .

HY-135564B

(Rac)-RK-682	Phosphatase	Cancer
(Rac)-RK-682, a racemate of RK-682, is a protein tyrosine phosphatases (PTPases) inhibitor. (Rac)-RK-682 inhibits protein tyrosine phosphatase 1B (PTP-1B), low molecular weight protein tyrosine phosphatases (LMW-PTP), and cell division cycle 25B (CDC-25B) with IC₅₀s of 8.6 μM, 12.4 μM, and 0.7 μM, respectively .

HY-P10574

Phosphorylated CHKtide	Checkpoint Kinase (Chk)	Cancer
Phosphorylated CHKtide is a synthetic peptide substrate derived from CDC25C, which is phosphorylated by CHK1/CHK2 in one of the DNA repair pathways. Phosphorylated CHKtide is used in the assays of cell cycle checkpoint kinases 1 and 2 (CHK1/CHK2) and salt-inducible kinases (SIKs) .

HY-RS11691

RASGRF1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
RASGRF1 Human Pre-designed siRNA Set A contains three designed siRNAs for RASGRF1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

RASGRF1 Human Pre-designed siRNA Set A RASGRF1 Human Pre-designed siRNA Set A

HY-RS17278

Cdc25a Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Cdc25a Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cdc25a gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cdc25a Mouse Pre-designed siRNA Set A Cdc25a Mouse Pre-designed siRNA Set A

HY-RS23732

Cdc25a Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Cdc25a Rat Pre-designed siRNA Set A contains three designed siRNAs for Cdc25a gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cdc25a Rat Pre-designed siRNA Set A Cdc25a Rat Pre-designed siRNA Set A

HY-178295

VHR-IN-5	Phosphatase	Cancer
VHR-IN-5 is a selective vaccinia H1-related (VHR) phosphatase inhibitor with an IC₅₀ of 78 nM. VHR-IN-5 shows very weaker inhibitory activity against MKP-1 (IC₅₀ = 0.78 μM), CD45 (IC₅₀ = 0.61 μM), Cdc25A (IC₅₀ = 3.4 μM), PTP1B (IC₅₀ = 1.8 μM), and HePTP (IC₅₀ = 1.5 μM). VHR-IN-5 inhibits the proliferation of HeLa cells. VHR-IN-5 can be used for the research of cervical cancer .

HY-RS25345

Cdc25c Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Cdc25c Rat Pre-designed siRNA Set A contains three designed siRNAs for Cdc25c gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cdc25c Rat Pre-designed siRNA Set A Cdc25c Rat Pre-designed siRNA Set A

HY-RS19767

Cdc25b Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Cdc25b Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cdc25b gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cdc25b Mouse Pre-designed siRNA Set A Cdc25b Mouse Pre-designed siRNA Set A

HY-RS26264

Cdc25b Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Cdc25b Rat Pre-designed siRNA Set A contains three designed siRNAs for Cdc25b gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cdc25b Rat Pre-designed siRNA Set A Cdc25b Rat Pre-designed siRNA Set A

HY-W276819

PLK1-IN-9	Polo-like Kinase (PLK)	Cancer
PLK1-IN-9 (Compound M2) is an inhibitor for polo-like kinase 1 (PLK1), that inhibits PLK proteins modified with peptides 1010pT, cdc25c and PBIP, with IC₅₀s of 1.6, 0.8 and 1.4 μM, respectively. PLK1-IN-9 inhibits proliferations of cancer cells HeLa, HL60, SNU387/499, HepG2, exhibits cytotoxicity and induces apoptosis. PLK1-IN-9 inhibits tumor growth in HepG2 xenograft mouse model .

HY-N7045R

Isosilybin B (Standard)	Reference Standards Androgen Receptor Apoptosis CDK Caspase PSMA	Cancer
Isosilybin B (Standard) is the analytical standard of Isosilybin B (HY-N7045). This product is intended for research and analytical applications. Isosilybin B is a flavonolignan. Isosilybin B can be isolated from Silybum marianum. Isosilybin B can regulate cell cycle-related proteins (e.g., reduce cyclins (D3, D1, A, E), Cdk4, Cdk2, *Cdc25A), and activate Caspases* (Caspase-9 and Caspase-3). Isosilybin B can promote Apoptosis, reduce androgen receptor (AR) and PSA. Isosilybin B has anticancer activity against prostate cancer .

HY-108543R

NSC 95397 (Standard)	Reference Standards Phosphatase Apoptosis	Cancer
NSC 95397 (Standard) is the analytical standard of NSC 95397 (HY-108543). This product is intended for research and analytical applications. NSC 95397 is a potent, selective Cdc25 dual specificity phosphatase inhibitor (K_i=32 nM (Cdc25A), 96 nM (Cdc25B), 40 nM (Cdc25C); IC₅₀=22.3 nM (human Cdc25A), 56.9 nM (human Cdc25C), 125 nM (Cdc25B)) . NSC 95397 inhibits mitogen-activated protein K_inase phosphatase-1 (MKP-1) and suppresses proliferation and induces apoptosis in colon cancer cells through MKP-1 and ERK1/2 pathway .

Cat. No.	Product Name	Target	Research Area

HY-P4979

Cdc25A (80-93) (human)	Biochemical Assay Reagents	Cancer
Cdc25A (80-93) (human) is a polypeptide that controls the cell proliferation and tumorigenesis by a change in expression of proteins involved in cyclin D1 regulation and G1/S transition. Cdc25A (80-93) (human) can be used in cancer research .

HY-P10574

Phosphorylated CHKtide	Checkpoint Kinase (Chk)	Cancer
Phosphorylated CHKtide is a synthetic peptide substrate derived from CDC25C, which is phosphorylated by CHK1/CHK2 in one of the DNA repair pathways. Phosphorylated CHKtide is used in the assays of cell cycle checkpoint kinases 1 and 2 (CHK1/CHK2) and salt-inducible kinases (SIKs) .

Host:	Mouse (3) Rabbit (6)
Reactivity:	Human (7) Mouse (2) Rat (3)
Application:	IHC-P (5) ICC/IF (4) IF-Tissue (1) IP (4) WB (9) FC (2) ELISA (4)
Isotype:	IgG (6) IgG1 (2)
Conjugation:	Non-conjugated (9)
Clonality:	Polyclonal (1) Monoclonal (5) Monoclonal Antibody (1) Recombinant (3)
Modification:	Unmodified (7)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P84245

	Cdc25C Antibody (YA3942) CDC25; CDC25C	WB, IHC-P, ELISA	Human
	Cdc25C Antibody (YA3942) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Cdc25C.

HY-P84245A

	Cdc25C Antibody (YA3942)(PBS only) CDC25; CDC25C	WB, IHC-P, ELISA	Human
	Cdc25C Antibody (YA3942) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Cdc25C.

HY-P82705

	CDC25 Antibody (YA2450) GNRP; GRF1; CDC25; GRF55; CDC25L; H-GRF55; PP13187; ras-GRF1	WB	Rat
	CDC25 Antibody (YA2450) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CDC25.

HY-P82705A

	CDC25 Antibody (YA2450)(PBS only) GNRP; GRF1; CDC25; GRF55; CDC25L; H-GRF55; PP13187; ras-GRF1	WB	Rat
	CDC25 Antibody (YA2450) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CDC25.

HY-P80072

	Cdc25B Antibody	WB, IP, IF-Tissue	Human, Mouse
	Cdc25B Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to Cdc25B.

HY-P82879

	Cdc25C Antibody (YA2624) CDC25C; M-phase inducer phosphatase 3; Dual specificity phosphatase CDC25C	WB, IHC-P, ICC/IF, IP, FC	Human
	Cdc25C Antibody (YA2624) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cdc25C.

HY-P85096

	Cdc25C Antibody (YA4788) CDC25C; M-phase inducer phosphatase 3; Dual specificity phosphatase CDC25C	WB, IHC-P, ICC/IF, ELISA	Human
	Cdc25C Antibody (YA4788) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to Cdc25C.

HY-P86209

	Cdc25C Antibody (YA5901) CDC25C; M-phase inducer phosphatase 3; Dual specificity phosphatase CDC25C	WB, IHC-P, ICC/IF, IP, ELISA	Human, Rat
	Cdc25C Antibody (YA5901) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cdc25C.

HY-P82405

	MARK3 Antibody (YA2150) C-TAK1 antibody; CDC25C associated protein kinase 1 antibody; CDC25C-associated protein kinase 1 antibody; cTAK1 antibody; ELKL motif kinase 2 antibody; EMK-2 antibody; Emk2 antibody; ETK 1 antibody; KIAA4230 antibody; KP78 antibody; MAP microtubule affinity regulating kinase 3 antibody; MAP/microtubule affinity-regulating kinase 3 antibody; Mark3 antibody; MARK3_HUMAN antibody; Par 1a antibody; PAR1A antibody; Protein kinase STK10 antibody; Ser/Thr protein kinase PAR-1 antibody; Serine threonine protein kinase p78 antibody; Serine/threonine-protein kinase p78 antibody; SerThr protein kinase PAR 1 antibody;	WB, ICC/IF, IP, FC	Mouse, Human
	MARK3 Antibody (YA2150) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MARK3.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks